Isembyld Approval: First Therapy Targeting Muscle Loss in SMA
FDA approved Isembyld, or apitegromab-mstn, for people age two and older with spinal muscular atrophy who are already receiving an SMN2-targeted treatment.
Timeline
- March 22, 2018: Apitegromab received an orphan-drug designation for spinal muscular atrophy.
- 52-week pivotal trial: Participants already taking SMN2-targeted therapy received Isembyld or placebo every four weeks.
- September 11, 2026: FDA approved Isembyld for adults and children age two and older in the labeled add-on setting.
The US Food and Drug Administration approved Isembyld, the brand name for apitegromab-mstn, on September 11, 2026. The indication covers adults and children age two and older with spinal muscular atrophy who are already receiving a treatment that targets the SMN2 gene. That combination requirement is a central part of the approved use. [1][2]
Spinal muscular atrophy is a rare genetic neuromuscular disease associated with an abnormal SMN1 gene and loss of motor neurons, leading to progressive weakness and muscle wasting. Existing SMN2-targeted medicines increase production of functional survival motor neuron protein. Isembyld addresses a different part of the disease by acting directly on skeletal muscle rather than replacing those treatments. [1]
FDA described Isembyld as the first approved SMA therapy that directly targets muscle loss. Apitegromab inhibits myostatin activation, a pathway that normally limits muscle growth. The intended strategy is to improve muscle function alongside therapy that supports motor-neuron survival. First in this category does not mean it reverses all established disability or works equally for every patient. [1]
The pivotal study was a 52-week randomized, double-blind, placebo-controlled trial with 188 participants ages two through 21 who could not move or walk independently. Everyone was already receiving an approved SMN2-targeted treatment. Participants received placebo or intravenous Isembyld at 10 or 20 milligrams per kilogram once every four weeks. [1]
The primary analysis included 156 children ages two through 12 and used the Hammersmith Functional Motor Scale Expanded. FDA reported a significant difference between 10-milligram-per-kilogram Isembyld and placebo at one year. A clinically meaningful improvement occurred in 34.2 percent of treated children versus 13.5 percent of those receiving placebo, a group comparison that cannot predict an individual's result. [1]
Common adverse reactions included upper-respiratory infections, vomiting, cough, other viral infections, headache, gastroenteritis and sore throat. FDA also reported an increased risk of fractures, including serious fractures, and warned about possible fetal harm and effects on reproductive function. Intravenous administration and these risks require specialist supervision and reference to the current prescribing information. [1]
Isembyld's significance is its add-on design: it approaches muscle weakness from a different biological direction while patients continue SMN2-targeted care. Eligibility begins at age two but also depends on diagnosis, existing treatment and clinical judgment. Families should discuss expected benefits, infusion logistics, fracture risk and alternatives with an SMA specialist rather than use headline results as personal treatment advice. [1][2]
Sources
- FDA — First therapy approved to target muscle loss in spinal muscular atrophy
- FDA — Isembyld orphan designation and approved indication